There are thought to be over 1.5 million species of fungi. Of these, most live on decaying vegetation; others exist in partnerships with algae (lichens) or tree roots (mycorrhizas), or are parasites of plants or insects. Only a few tens of species cause any direct harm to humans, but in forthcoming issues the Mycologist will feature a series of articles about some of the principal species of fungi that do cause irritating, and in some cases life-threaten ing, hum an infections. In this issue Candida albicans, the m ajor serious hum an pathogen, is introduced.
serious infections in which microbes enter the blood stream (septicaemia) and then challenge the function ing of the vital organs, the fungus Candida albicans (Robin) Berkhout has risen through the ranks of obscu rity to rival some of the most common bacterial septi caemias (Calderone, 2 0 0 2 ). It may not be appreciated th a t there are m any m ore Candida infections and Candida-related deaths than there are, for example, cases of bacterial meningitis. In fact, there is a small group of Candida species that cause disease of which C. albicans is the most common and important. It is therefore right to know this yeast as fungal public enemy number one. If a doctor diagnoses a bacterial blood infection, in most cases a number of antibiotics can be used to treat the condition. Unfortunately, fungi share many of the same basic biochemical pathways as hum ans and so our opportunities to intervene using therapeutic drugs that discriminate between hum an and fungal target enzymes or biochemical steps are far fewer. Consequently, Candida and other fungal septicaemias are perilously difficult to treat, and the treatm ent is frequently unsuccessful, so that deaths rates may be as much as 3 0 -5 0 % in spite of antifungal treatm ent.
Mercifully Candida septicaemias are still relatively rare, and they are alm ost non-existent in norm al healthy people. Indeed, Candida blood infection is often said to be a 'disease of the diseased' since it is only seen when a patient's norm al immune system is laid low by some other condition or treatm ent. For example, a patient undergoing a bone marrow or kidney or heart transplant takes immune-suppressing agents to damp en down immunity to prevent the body rejecting the marrow or organ graft. This opens the door for so-called 'opportunistic' infections like those blood infections caused by C. albicans. It should be remembered that amongst healthy people at least 50% carry the organ ism in the gut, vagina or skin most of the time, and without any signs of infection at all. The organism is clearly adapted to life as a com m ensal and its transition from a benign Dr Jekyll to an aggressive Mr Hyde is real ly an unfortunate accident due to the progress and availability of medical treatm ents for other medical conditions. Therefore, it is medical progress itself that accounts for the m eteoric rise in the num bers of Candida-associated infections and deaths in recent years.
Although, as mentioned above, serious infections are rare and invariably associated with another influence on normal immunity, these rules do not always apply as strongly to an entirely different form of the disease repertoire caused by Candida species -namely 'thrush' or 'yeast infections'. These infections are caused on mucous membranes, most commonly in the vagina or in the m outh (Fig 1) . Again, an episode of thrush is often related to some other d isturbance of the balance between the infectious capability of the fungus and the co n stan t surveillance of the im m une system. Antibiotics th at wipe out the com peting bacterial microflora, such as gut anaerobes and lactobaccilli, can let the fungus grow unchecked. Despite contrary claims, there is little definitive evidence that taking oral contra- W hat of the current state of our understanding of why this fungus causes hum an infections? This is a huge area of highly active research (Calderone, 2 0 0 2 ). Clearly, the situation is very different from that for many bacteri al pathogens when the disease is often explainable simply in terms of the effects of a specific toxin. No toxin, no dis ease. Pathogenic Candida species produce no known toxin, but they do have a battery of enzymes such as secreted proteases, lipases and phospholipases. that can degrade hum an tissues. Candida proteases in particular seem to be an important aspect of virulence. There are also many adhesive molecules, such as mannoproteins on the surface of the cell wall of the fungus that enable the fungus to hang on tenaciously to hum an epithelia in the gut, vagina, and linings of blood vessels. Finally, the ability of the fungus to form filaments seems to be a part of the repertoire of virulence factors that make this one of the most feared and common fungi that attack hum an beings. Progress is being made. Techniques have been developed that enable molecular biology to take its part in defining the genes that are required for virulence and the targets for future new generations of antifungal drugs. The need now is to translate our increasing under standing of the biology of this organism into practical benefits such as the development of new treatments.
Nevertheless, it seems certain that for the foresee able future C. albitw is will rem ain a m ajor clinical prob lem and an im portant agent of microbial disease. 
R e feren ces

Section II contains five short chapters on aspects of
Fusarium genetics, quite difficult in parts but im mense ly satisfying. We are now in a position to appreciate, for example, the huge contribution that vegetative com pat ibility studies (Chapter 6) are making to our under standing of the evolution and distribution of the impor tant plant pathogens in the F. oxysporum and G. fujikuroi groups (examples of which are the subjects of later chapters).
Section III has four chapters on Ecology, ranging from a study of biogeography, exemplified by the evolu tion and adaptations of two species occurrin g in Australia (Chapter 9), to an unexpected but interesting
